BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information Letter on Reminyl®: Serious skin reactions; Stevens-Johnson Syndrome and acute generalised exanthematous pustulosis

2015.09.22

Active substance: Galantaminhydrobromid

The company Janssen-Cilag is circulating information on a new warning for Reminyl®.

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 377KB, File is accessible